Voglio sapere a riguardo di…

jbell on DSKJLSW7X2PROD with NOTICES

Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices behaviors, tachycardia, and hypertension. There are no commercial or approved medical uses for MDMB4en-PINACA and it is not a controlled substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if MDMB-4en-PINACA is controlled under Schedule II of the 1971 Convention.
3-Methoxyphencyclidine; chemical name: 1-1-3-methoxyphenyl cyclohexylpiperidine is a novel Nmethyl-D-aspartate NMDA receptor antagonist with structural and biochemical similarities to phencyclcycidine PCP and other arylcyclohexylamines. 3Methoxyphencyclidine is classified as an arylcyclohexylamine and produces dissociative anesthetic and hallucinogenic effects. Use of this substance is associated with intoxication and published case reports of both fatal and non-fatal overdose. 3Methoxyphencyclidine is encountered by law enforcement in drug seizure reports. 3-Methoxyphencyclidine is an analogue of the Schedule II
hallucinogen PCP. There is no approved medical use for 3Methoxyphencyclidine in the United States and is not a controlled substance under the CSA. If intended for human consumption, 3-Methoxyphencyclidine may be treated as a controlled substance analogue under the CSA
pursuant to 21 U.S.C. 80232A and 813. As such, additional permanent controls will be necessary to fulfill U.S.
obligations if 3-Methoxyphencyclidine is controlled under Schedule II of the 1971 Convention.
Diphenidine chemical name: 1-1,2diphenylethyl piperidine is a noncompetitive NMDA receptor antagonist classified as a diarylethylamine and produces dissociative anesthetic and hallucinogenic effects. It was originally synthesized in the 1920s but reports of abuse started in the last decade. Use of this substance is associated with intoxication and published case reports of both fatal and non-fatal overdose outside of the United States.
Diphenidine is encountered by law enforcement in drug seizure reports.
Diphenidine is not approved for medical use in the United States and is not a controlled substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S.
obligations if diphenidine is controlled under Schedule II of the 1971
Convention.
Flubromazolam, clonazolam, and diclazepam belong to a class of substances known as benzodiazepines.
Benzodiazepines produce central nervous system depression and are
VerDate Sep<11>2014

17:47 Feb 17, 2021

Jkt 253001

commonly used to treat insomnia, anxiety, and seizure disorders.
Flubromazolam is a triazole analogue of the designer benzodiazepine, flubromazepam. Flubromazolam can be purchased on the internet and is used as a recreational substance in the United States. Flubromazolam has been identified in an increasing number of law enforcement seizures and has been associated with an increasing number of drug overdose deaths. According to the NFLIS database, in 2020 there were 1,446 clonazolam encounters as of December 2020. It is abused by a broad range of groups including youths, young adults, and older adults. Clonazolam has been involved in an increasing number of drug seizure events as well as drug overdose deaths, alone and in combination with alcohol. As such, the NFLIS database reported 249 encounters in 2020 as of December 2020.
Diclazepam is a designer benzodiazepine sold on the internet and most often found as a liquid solution, but it may be sold as a powder, tablet, blotter paper, or pellet. In 2020, the NFLIS database reported 113 encounters of diclazepam as of December 2020. In 2018, flubromazolam, clonazolam, and dicalazepam were all identified by law enforcement in driving under the influence of drugs cases in the United States. Flubromazolam, clonazolam, and diclazepam are not approved for medical use in the United States and are not controlled substances under the CSA. As such, additional permanent controls will be necessary to fulfill U.S.
obligations if flubromazolam, clonazolam, and dicalazepam are controlled under Schedule IV of the 1971 Convention.
FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 201d2B of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the 1971 Convention at the CND meeting in April 2021.
Comments regarding the WHO
recommendations for control of isotonitazene under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the U.S. position regarding narcotic substances at the CND meeting.

PO 00000

Frm 00070

Fmt 4703

Sfmt 4703

10103

Dated: February 12, 2021.
Lauren K. Roth, Acting Principal Associate Commissioner for Policy.
FR Doc. 202103268 Filed 21721; 8:45 am BILLING CODE 416401P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEP
SIP21008, Examining Approaches to Improve Care and Management of People with Lupus.
Date: May 13, 2021.
Time: 11:00 a.m.6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
Jaya Raman, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S1078, Atlanta, Georgia 30341, Telephone 770
4886511, JRaman@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and
FOR FURTHER INFORMATION CONTACT:

E:FRFM18FEN1.SGM

18FEN1